Life Molecular Imaging
Richard Keegan, Ph.D. has a diverse work experience in various companies and organizations. Richard started their career as an intern at St. Vincent's Hospital in 2009 and later worked as a researcher at Sacred Heart University. In 2013, they became a clinical research coordinator at Cardiology Associates of Fairfield County.
From 2014 to 2020, Richard worked in different roles at different companies. Richard was involved in molecular neuroimaging at The Institute for Neurodegenerative Disorders and research and development at Unilever, where they developed and followed SOPs for various protein assays, lipid extractions, LC/MS preparations, data analysis, and more. At AxioMx Inc, they worked as an associate research scientist.
Richard's most recent role is as the Regional Medical Director-Northeast at Life Molecular Imaging, where they started in 2020. Prior to that, they were a PhD candidate and later a PhD student at Stony Brook University, focusing on their research in the field.
Overall, Richard Keegan, Ph.D. has a strong background in research, clinical coordination, and molecular imaging, with expertise in various scientific techniques and multidisciplinary work.
Richard Keegan, Ph.D. has an education history that includes a Bachelor of Science (B.S.) degree in Neuroscience from Sacred Heart University, which they completed from 2009 to 2013. Richard furthered their education at Stony Brook University Graduate School, where they obtained a Doctor of Philosophy (PhD) degree in Neuroscience from 2015 to 2020.
This person is not in any offices
Life Molecular Imaging
Life Molecular Imaging (formerly Piramal Imaging) is now part of the Alliance Medical Group, an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allow physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine. With an ever increasing demand of effective care as well as a growing global awareness of healthcare efficiency and costs, improved diagnostic tools offer a unique opportunity for: - Earlier detection and better characterization of diseases - Determining the right therapy at the right dose for a patient (precision medicine) - Monitoring therapy response As a global leader in the field of radiopharmaceuticals, Life Molecular Imaging is developing a product portfolio of innovative molecular imaging probes that address major clinical needs in neurology, oncology, and cardiology. Life Molecular Imaging is supporting use of imaging biomarkers in several major therapeutic trials in Alzheimer’s disease. Imprint: Life Molecular Imaging GmbH Tegeler Strasse 6-7 13353 Berlin Germany Telefon: +49 30 461 124603 Fax: +49 30 461 124 629 Email: info@life-mi.com Internet: http://www.life-mi.com Managing Directors: Dr. Ludger Dinkelborg Michel Jongens Chamber of Commerce: Amtsgericht Charlottenburg HRB 136823 B Sales tax identification number: DE 283685037 Data Protection Policy: https://life-mi.com/data-protection/